SURVYR

QTTB

Q32 Bio Inc.
$9.06
+$0.35 (4.02%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-32%+161%+355%+548%+742%Oct 2025Oct 2026Apr 202652w high $23.5752w low $1.91
QTTBSPY
Wall St. Highest PT $59.00 (+551.2%) Wall St. Avg PT $39.67 (+337.8%)
$2$17$31$46$61POC $5Hi $59Avg $40
Underwater Drawdown %Max DD -64.8%Current -57.6%
0.0%-64.8%
Relative Strength vs SPY+209.6% vs SPYOutperforming
+751%0%-751%
1W
+$0.39 (4.50%)
1M
−$0.17 (1.84%)
3M
−$5.58 (38.11%)
6M
+$3.56 (64.73%)
YTD
+$5.74 (172.89%)
1Y
+$6.50 (253.91%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
6 analysts · mean score 1.14
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$9.06
Average target$39.67
+$30.61 (+337.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$29.00
Median$39.67
High$59.00
12-month Wall Street target range
Recent analyst rating changes · 27
Initiated
2026-10-12 · Leerink Partners started covering QTTB at Outperform
Initiated
2026-09-28 · Jefferies started covering QTTB at Buy
Initiated
2026-08-24 · Morgan Stanley started covering QTTB at Overweight
Reiterated
2026-07-28 · HC Wainwright & Co. reiterated Buy on QTTB
Reiterated
2026-07-13 · Oppenheimer reiterated Outperform on QTTB
Upgrade
2026-07-13 · Wells Fargo upgraded QTTB from Equal-Weight to Overweight
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$257.5M
P/E (last 12 months)2.8
P/E (next 12 months, estimated)-8.5
52-week range$1.91 – $23.57
Dividend yieldNo dividend
Analyst consensusStrong Buy (6)
Average analyst price target$39.67 (+338%)

What they do

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for QTTB yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

QTTB earningsNo upcoming date on file
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.44est -$0.54+18.8%Above estimates
May 5, 2026-$0.54est -$0.68+20.6%Above estimates
Mar 10, 2026$4.58est -$0.86+632.6%Above estimates
Nov 13, 2025-$0.60est -$1.19+49.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-23 23:44:25 ET
24-1125-0325-0525-0825-1126-0326-0526-08-1.534.58
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$53.7M–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
Barrons.com · Oct 01
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
PR Newswire · Sep 30
Top Premarket Gainers
MT Newswires · Sep 30
Top Premarket Gainers
MT Newswires · Sep 29
Jefferies Initiates Q32 Bio at Buy With $29 Price Target
MT Newswires · Sep 28
Rating changes
Initiated
2026-10-12 · Leerink Partners started covering QTTB at Outperform
Initiated
2026-09-28 · Jefferies started covering QTTB at Buy
Initiated
2026-08-24 · Morgan Stanley started covering QTTB at Overweight
Reiterated
2026-07-28 · HC Wainwright & Co. reiterated Buy on QTTB
Reiterated
2026-07-13 · Oppenheimer reiterated Outperform on QTTB
Upgrade
2026-07-13 · Wells Fargo upgraded QTTB from Equal-Weight to Overweight

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Kalowski Lee
CFO and President · 2026-10-06
Sell
$10.8K
Violette Shelia M.
Chief Scientific Officer · 2026-10-06
Sell
$7.6K
Morrison Jodie Pope
Director, CEO · 2026-10-06
Sell
$26.8K
Violette Shelia M.
Chief Scientific Officer · 2026-08-25
Sell
$46.3K
Kalowski Lee
CFO and President · 2026-08-25
Sell
$65.8K
Morrison Jodie Pope
Director, CEO · 2026-08-25
Sell
$163.0K

Stats refreshed 2026-10-23 23:44:25 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026